|
Market Closed -
Other stock markets
|
Pre-market 13:37:08 | |||
| 25.68 USD | -3.02% |
|
25.75 | +0.27% |
| 05-09 | Ireland's fiscal success faces the risk of over-reliance |  |
| 05-06 | CellCentric Ltd announced that it has received $220 million in funding from a group of investors | CI |
Business description: Pfizer Inc.
- primary care products (47.4%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.;
- specialty care products (26.2%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.;
- oncology products (24.5%);
- other (1.9%).
The United States accounts for 60.8% of net sales.
Number of employees: 75,000
Sales by Activity: Pfizer Inc.
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Global Biopharmaceuticals Business (Biopharma) | 79.56B | 98.99B | 57.19B | 62.4B | 61.2B |
Pfizer Centreone (PC1) | - | - | - | 1.15B | 1.34B |
Pfizer Ignite | - | - | - | 82M | 41M |
Other business activities | 1.73B | 1.34B | 1.31B | - | - |
Geographical breakdown of sales: Pfizer Inc.
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
United States | 29.75B | 42.47B | 27.09B | 38.69B | 37.08B |
Developed Markets | - | - | - | 16.06B | 16.19B |
Emerging Markets | 20.7B | 20.1B | 12B | 8.88B | 9.31B |
Developed Europe | 18.34B | 21.98B | 11.65B | - | - |
International | 12.51B | 15.78B | 7.76B | - | - |
Executive Committee: Pfizer Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Albert Bourla
CEO | Chief Executive Officer | 64 | 31/12/2018 |
David Denton
DFI | Director of Finance/CFO | 61 | 01/05/2022 |
| Chief Tech/Sci/R&D Officer | - | 31/12/2006 | |
| Chief Tech/Sci/R&D Officer | - | 23/02/2025 | |
Chris Boshoff
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/2024 |
Composition of the Board of Directors: Pfizer Inc.
| Director | Title | Age | Since |
|---|---|---|---|
Suzanne Johnson
BRD | Director/Board Member | 68 | 31/08/2007 |
Shantanu Narayen
BRD | Director/Board Member | 62 | 26/09/2013 |
Albert Bourla
CHM | Chairman | 64 | 31/12/2019 |
Jim Smith
BRD | Director/Board Member | 66 | 25/06/2014 |
| Director/Board Member | 69 | 24/06/2015 | |
Ronald Blaylock
BRD | Director/Board Member | 65 | 22/02/2017 |
Dan Littman
BRD | Director/Board Member | 73 | 04/03/2018 |
Scott Gottlieb
BRD | Director/Board Member | 54 | 26/06/2019 |
James Quincey
BRD | Director/Board Member | 61 | 26/02/2020 |
| Director/Board Member | 68 | 31/03/2020 |
Holdings: Pfizer Inc.
| Name | Equities | % | Valuation |
|---|---|---|---|
PFIZER LIMITED 63.92% | 29,243,042 | 63.92% | 1 451 M $ |
CSTONE PHARMACEUTICALS 7.24% | 115,928,803 | 7.24% | 138 M $ |
| 5,376,344 | 5.36% | 53 M $ | |
| 22,032,040 | 6.65% | 47 M $ | |
CELCUITY INC. 0.76% | 349,406 | 0.76% | 42 M $ |
ARVINAS, INC. 5.41% | 3,457,815 | 5.41% | 34 M $ |
VALNEVA SE 5.55% | 9,554,395 | 5.55% | 26 M $ |
ZURA BIO LIMITED 3.13% | 2,970,022 | 3.13% | 15 M $ |
WAVE LIFE SCIENCES LTD. 0.97% | 1,875,000 | 0.97% | 13 M $ |
PYXIS ONCOLOGY, INC. 11.19% | 7,032,770 | 11.19% | 12 M $ |
Company details: Pfizer Inc.
Group companies: Pfizer Inc.
| Name | Category and Sector |
|---|---|
Pfizer PFE Italy Holdco SARL | |
Pfizer Europe Holdings SARL
 Pfizer Europe Holdings SARL Financial ConglomeratesFinance Functions as an investment holding company |
Financial Conglomerates
|
Pfizer Group Luxembourg SARL
 Pfizer Group Luxembourg SARL Financial ConglomeratesFinance Provides miscellaneous intermediation services |
Financial Conglomerates
|
Pfizer Group Luxembourg SARL
Pfizer Group Luxembourg SARL Financial ConglomeratesFinance Provides miscellaneous intermediation services |
Financial Conglomerates
|
Pfizer Ireland Pharmaceuticals ULC
 Pfizer Ireland Pharmaceuticals ULC Financial ConglomeratesFinance Provides financial intermediation services |
Financial Conglomerates
|
Other Pharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.02% | -2.47% | +15.26% | -32.95% | 146B | |
| -2.72% | -1.54% | +29.12% | +117.57% | 846B | |
| -0.53% | -2.58% | +43.51% | +36.91% | 533B | |
| -0.57% | -2.44% | +9.18% | +37.65% | 356B | |
| +0.78% | -0.97% | +22.40% | +12.53% | 324B | |
| +1.07% | +1.32% | +31.48% | +13.27% | 282B | |
| +0.29% | -0.09% | +24.06% | +22.86% | 278B | |
| -0.82% | -0.70% | +46.61% | -5.53% | 275B | |
| +3.23% | +5.97% | -32.07% | -48.10% | 203B | |
| +0.79% | +0.57% | +24.76% | +41.69% | 179B | |
| Average | +0.61% | -0.85% | +21.43% | +19.59% | 342.17B | |
| Weighted average by Cap. | +0.41% | -1.22% | +25.39% | +40.34% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- PFE Stock
- Company Pfizer Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition